These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9584298)

  • 21. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
    Stevens SK; Haffajee CI; Naccarelli GV; Schwartz KM; Luceri RM; Packer DL; Rubin AM; Kowey PR
    J Am Coll Cardiol; 1996 Aug; 28(2):418-22. PubMed ID: 8800119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Relationship Between Cardiac Vulnerability and Restitution Properties of the Ventricular Activation Recovery Interval.
    Yamashita S; Yoshida A; Fukuzawa K; Nakanishi T; Matsumoto A; Konishi H; Ichibori H; Hyogo K; Imada H; Hirata K
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):768-73. PubMed ID: 25810143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upper limit of vulnerability predicts chronic defibrillation threshold for transvenous implantable defibrillators.
    Martin DJ; Chen PS; Hwang C; Gang ES; Mandel WJ; Peter CT; Swerdlow CD
    J Cardiovasc Electrophysiol; 1997 Mar; 8(3):241-8. PubMed ID: 9083873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal strength and number of shocks at upper limit of vulnerability testing required to predict high defibrillation threshold without inducing ventricular fibrillation.
    Takami K; Yoshida A; Fukuzawa K; Takei A; Kiuchi K; Kanda G; Kumagai H; Takami M; Torii-Tanaka S; Itoh M; Imamura K; Fujiwara R; Suzuki A; Nakanishi T; Yamashita S; Matsumoto A; Hirata K
    Circ J; 2013; 77(10):2490-6. PubMed ID: 23877733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of upper limit of vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system.
    Souza JJ; Malkin RA; Ideker RE
    Circulation; 1995 Feb; 91(4):1247-52. PubMed ID: 7850965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry.
    Arnson Y; Suleiman M; Glikson M; Sela R; Geist M; Amit G; Schliamser JE; Goldenberg I; Ben-Zvi S; Orvin K; Rosenheck S; Adam Freedberg N; Strasberg B; Haim M
    Heart Rhythm; 2014 May; 11(5):814-21. PubMed ID: 24486799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate reproducibility of upper limit of vulnerability measurements in patients undergoing transvenous implantable cardioverter defibrillator implantation.
    Ellenbogen KA; Wood MA; Gilligan DM; Crofts T; London W; McClish D
    J Cardiovasc Electrophysiol; 1998 Jun; 9(6):588-95. PubMed ID: 9654223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved defibrillation efficacy with an ascending ramp waveform in humans.
    Shorofsky SR; Rashba E; Havel W; Belk P; Degroot P; Swerdlow C; Gold MR
    Heart Rhythm; 2005 Apr; 2(4):388-94. PubMed ID: 15851341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ICD Shock, Not Ventricular Fibrillation, Causes Elevation of High Sensitive Troponin T after Defibrillation Threshold Testing--The Prospective, Randomized, Multicentre TropShock-Trial.
    Semmler V; Biermann J; Haller B; Jilek C; Sarafoff N; Lennerz C; Vrazic H; Zrenner B; Asbach S; Kolb C
    PLoS One; 2015; 10(7):e0131570. PubMed ID: 26208329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Truncated biphasic pulses for transthoracic defibrillation.
    Bardy GH; Gliner BE; Kudenchuk PJ; Poole JE; Dolack GL; Jones GK; Anderson J; Troutman C; Johnson G
    Circulation; 1995 Mar; 91(6):1768-74. PubMed ID: 7882486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of the upper limit of vulnerability during defibrillator implantation can substitute defibrillation threshold measurement.
    Bessho R; Tanaka S
    Int J Artif Organs; 1998 Mar; 21(3):151-60. PubMed ID: 9622114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of myocardial ischemia on ventricular fibrillation inducibility and defibrillation efficacy.
    Behrens S; Li C; Franz MR
    J Am Coll Cardiol; 1997 Mar; 29(4):817-24. PubMed ID: 9091529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracardiac atrial defibrillation.
    Dosdall DJ; Ideker RE
    Heart Rhythm; 2007 Mar; 4(3 Suppl):S51-6. PubMed ID: 17336885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Automatic determination of timing intervals for upper limit of vulnerability using ICD electrograms.
    Shehata M; Belk P; Kremers M; Saba S; Cao J; Swerdlow CD
    Pacing Clin Electrophysiol; 2008 Jun; 31(6):691-700. PubMed ID: 18507541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of shock waveform configuration on the defibrillation capacity of implantable cardioverter defibrillators in dogs.
    Pariaut R; Saelinger C; Vila J; Deforge W; Queiroz-Williams P; Beaufrère H; Zimmerman M; Saile K; Reynolds CA
    J Vet Cardiol; 2012 Sep; 14(3):389-98. PubMed ID: 22819488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators.
    Hou CJ; Chang-Sing P; Flynn E; Martinez L; Peterson J; Ottoboni LK; Liem LB; Sung RJ
    Circulation; 1995 Nov; 92(9):2558-64. PubMed ID: 7586357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ventricular pacing threshold and refractoriness after defibrillation shocks in patients with implantable cardioverter-defibrillators.
    Yu JC; Lauer MR; Young C; Liem B; Peterson J; Ottoboni L; Sung RJ
    Am Heart J; 1996 Jun; 131(6):1121-6. PubMed ID: 8644590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of defibrillation efficacy in patients undergoing epicardial defibrillator implantation. The Multicenter Pacemaker-Cardioverter-Defibrillator (PCD) Investigators Group.
    Leitch JW; Yee R
    J Am Coll Cardiol; 1993 Jun; 21(7):1632-7. PubMed ID: 8496530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.